Case Report: Late Onset of Myelodysplastic Syndrome From Donor Progenitor Cells After Allogeneic Stem Cell Transplantation. Which Lessons Can We Draw From the Reported Case?
donor cell myelodysplasia
immunosuppression
immunosurveillance
leukemogenesis
stem cells
transplant
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
21
05
2020
accepted:
21
09
2020
entrez:
12
11
2020
pubmed:
13
11
2020
medline:
13
11
2020
Statut:
epublish
Résumé
Myelodysplastic syndromes and acute leukemias after allogeneic stem cell transplantation (allo-SCT) are mainly caused by recurrence of the primitive leukemic clones. More rarely, they originate from donor hematopoietic stem cells, developing the so-called donor cell leukemia (DCL) or myelodysplastic syndromes (DC-MDSs). DCL and DC-MDS can be considered as an We report a case of DC-MDS diagnosed 5 years after an allo-SCT from a matched related donor (patient's sister) in a patient with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia (Ph+ B-ALL). The sex-mismatch allowed us to identify the donor cell origin. At the onset, the DC-MDS was characterized by chromosome seven monosomy and This case report highlights the need, whenever possible, to evaluate the donor origin of the posttransplant myelodysplasia and acute leukemias. The potential key role of the impaired immune surveillance and of long-lasting immunosuppression appears to be emerging in the development of this case of DC-MDS. Finally, this case reminds the importance to investigate the familiar genetic predisposition in donors with a familiar history of neoplasia.
Sections du résumé
BACKGROUND
BACKGROUND
Myelodysplastic syndromes and acute leukemias after allogeneic stem cell transplantation (allo-SCT) are mainly caused by recurrence of the primitive leukemic clones. More rarely, they originate from donor hematopoietic stem cells, developing the so-called donor cell leukemia (DCL) or myelodysplastic syndromes (DC-MDSs). DCL and DC-MDS can be considered as an
CASE PRESENTATION
METHODS
We report a case of DC-MDS diagnosed 5 years after an allo-SCT from a matched related donor (patient's sister) in a patient with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia (Ph+ B-ALL). The sex-mismatch allowed us to identify the donor cell origin. At the onset, the DC-MDS was characterized by chromosome seven monosomy and
CONCLUSION
CONCLUSIONS
This case report highlights the need, whenever possible, to evaluate the donor origin of the posttransplant myelodysplasia and acute leukemias. The potential key role of the impaired immune surveillance and of long-lasting immunosuppression appears to be emerging in the development of this case of DC-MDS. Finally, this case reminds the importance to investigate the familiar genetic predisposition in donors with a familiar history of neoplasia.
Identifiants
pubmed: 33178592
doi: 10.3389/fonc.2020.564521
pmc: PMC7591784
doi:
Types de publication
Journal Article
Langues
eng
Pagination
564521Informations de copyright
Copyright © 2020 Farina, Bernardi, Gandolfi, Zanaglio, Morello, Turra, Zollner, Gramegna, Rambaldi, Cattina, Polverelli, Malagola and Russo.
Références
Hematology Am Soc Hematol Educ Program. 2008;:142-9
pubmed: 19074072
PLoS One. 2017 Apr 11;12(4):e0175337
pubmed: 28399164
Bone Marrow Transplant. 2004 Apr;33(8):859-61
pubmed: 14743194
Blood. 2017 Jan 5;129(1):30-37
pubmed: 27821503
Leuk Lymphoma. 2007 Jan;48(1):25-38
pubmed: 17325845
Bone Marrow Transplant. 2005 Sep;36(5):471-2
pubmed: 15995709
Leukemia. 2020 Sep;34(9):2441-2450
pubmed: 32066866
Proc Natl Acad Sci U S A. 1967 Oct;58(4):1468-71
pubmed: 5237880
Leukemia. 2017 Jul;31(7):1637-1640
pubmed: 28348390
Lancet. 1971 Feb 6;1(7693):251-5
pubmed: 4100012
J Clin Oncol. 2000 Jan;18(2):348-57
pubmed: 10637249
Leukemia. 2016 Sep;30(9):1916-1920
pubmed: 26975880
Mediterr J Hematol Infect Dis. 2017 Jun 20;9(1):e2017036
pubmed: 28698779
Clin Immunol. 2010 Aug;136(2):217-27
pubmed: 20452829
J Clin Invest. 2019 Feb 1;129(2):476-488
pubmed: 30707109
Haematologica. 2005 Jul;90(7):969-75
pubmed: 15996934
Biol Blood Marrow Transplant. 2016 Jan;22(1):4-10
pubmed: 26386318
Transpl Infect Dis. 2014 Oct;16(5):697-712
pubmed: 25040166
PLoS One. 2017 Feb 23;12(2):e0172430
pubmed: 28231331
Blood. 2009 Jan 29;113(5):1175-83
pubmed: 18971419
Haematologica. 2009 Apr;94(4):542-9
pubmed: 19278968
Am J Hematol. 2016 May;91(5):507-17
pubmed: 26822317
Leuk Res. 1999 Mar;23(3):239-46
pubmed: 10071075
Am J Hematol. 2004 Aug;76(4):389-94
pubmed: 15282676
Am J Clin Pathol. 2011 Apr;135(4):501-4
pubmed: 21411772
Biol Blood Marrow Transplant. 2006 May;12(5):511-7
pubmed: 16635786
Allergy Asthma Clin Immunol. 2018 Sep 12;14(Suppl 2):61
pubmed: 30275850
Br J Haematol. 2014 Jul;166(2):209-12
pubmed: 24661075
Nature. 2010 Apr 8;464(7290):852-7
pubmed: 20305640
Oncotarget. 2016 Aug 23;7(34):55264-55275
pubmed: 27419369
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Bone Marrow Transplant. 2002 Jun;29(12):999-1003
pubmed: 12098070
Leukemia. 2019 Feb;33(2):508-517
pubmed: 30050122
Am J Hematol. 2012 Sep;87(9):916-22
pubmed: 22473867
N Engl J Med. 2011 Jun 30;364(26):2496-506
pubmed: 21714648
J Transl Med. 2017 Apr 5;15(1):70
pubmed: 28381232
Am J Clin Pathol. 2011 Apr;135(4):525-40
pubmed: 21411775
Biol Blood Marrow Transplant. 2011 Jun;17(6):771-89
pubmed: 20951819
Case Rep Hematol. 2020 Jan 11;2020:2795656
pubmed: 32148977
Blood. 2020 May 14;135(20):1729-1738
pubmed: 32232484
Blood. 2007 Oct 1;110(7):2744-8
pubmed: 17595333
J Clin Oncol. 2004 Mar 15;22(6):1136-51
pubmed: 15020616
Leukemia. 2006 Sep;20(9):1633-4
pubmed: 16791267
Nat Med. 2013 Nov;19(11):1513-7
pubmed: 24162813
Int J Mol Sci. 2016 Apr 13;17(4):553
pubmed: 27089321